Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study.

Purpose: Existing anti-epileptic drugs (AED) have limited efficiency in many patients, necessitating the search for alternative approaches such as stem cell therapy. We report the use of autologous patient-derived mesenchymal stem cells (MSC) as a therapeutic agent in symptomatic drug-resistant epilepsy in a Phase I open label clinical trial (registered as NCT02497443).

Patients And Methods: The patients received either standard treatment with AED (control group), or AED supplemented with single intravenous administration of undifferentiated autologous MSC (target dose of 1×10cells/kg), followed by a single intrathecal injection of neurally induced autologous MSC (target dose of 0.

[Periods in the working cycle and morbidity of submarine personnel on long-term self-sufficient cruises].

The authors review literature dedicated to the attempts at defining periods within the working cycle of nuclear submarine personnel on long-term self-sufficing cruises, and propose own definition of periods. Characteristics of the epidemiological process in pressurized vehicles are described. The general morbidity is presented in values of an intensive index.

[The health of the command officer staff doing their service in Polar regions].

Initial referral (not considering dental diseases) for the last 4 years was analyzed in servicemen from the Northern Fleet, group of navy specialists serving in Headquarters was investigated. Anamnesis and central hemodynamic parameters were studied in casual sample (388 senior officers), special questionnaires were used to determine intensity of service activity. According to the data obtained during the last 4 years level of morbidity, hospitalization and disability (without dental diseases) in servicemen constituted 857.